PIK3CG and colorectal carcinoma: Therefore, our motivation was to overcome this constraint and test the inhibition of PI3K p110α as a therapeutic approach since the activation of this specific isoform has been implicated in CRC progression and KRAS mutants are able to signal through this pathway [4, 29].